The Freedom Stack: Safety Profile & Research Summary
$513.84 Β· Free BAC water + free U.S. shipping Β· Same-day dispatch before 2 PM ET Β· FOR RESEARCH USE ONLY
Buy Freedom Research KitResearch Summary (Component-Level)
No peer-reviewed study has evaluated this five-vial stack as a unit. The table below lists representative findings for each component individually. Full per-component data and complete reference lists are on the dedicated GLP3-R, SS-31, and KLOW pages.
| Component | Representative Study | Reported Observation | Ref |
|---|---|---|---|
| GLP3-R | Coskun et al. (2022) β discovery | Characterized as a triple glucagon, GIP, and GLP-1 receptor agonist | [1] |
| GLP3-R | Urva et al. (2022) β phase 1b | Multiple-ascending-dose clinical pharmacology | [2] |
| SS-31 | Birk et al. (2013) β ischemic mitochondria | Reported re-energization of ischemic mitochondria via cardiolipin interaction | [6] |
| SS-31 | Chiao et al. (2020) β old mice | Reported late-life restoration of mitochondrial function | [10] |
| KLOW / GHK-Cu | Pickart & Margolina (2018) β gene data review | Reviewed regenerative and protective actions in light of gene-expression data | [12] |
| KLOW / BPC-157 | Hsieh et al. (2017) β endothelial models | Pro-angiogenic activity associated with VEGFR2 activation | [15] |
For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
βResearch Summary (Component-Level) No peer-reviewed study has evaluated this five-vial stack as a unit.β
References
- Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9.
- Urva S, Coskun T, Loh MT, et al. Lancet. 2022;400(10366):1869-1881.
- Jastreboff AM, Kaplan LM, FrΓas JP, et al. N Engl J Med. 2023;389(6):514-526.
- Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023;402(10401):529-544.
- Szeto HH. British Journal of Pharmacology. 2014;171(8):2029-2050.
- Birk AV, Liu S, Soong Y, et al. The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin. Journal of the American Society of Nephrology. 2013;24(8):1250-1261.
- Birk AV, Chao WM, Bracken C, et al. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology. 2014;171(8):2017-2028.
- Campbell MD, Duan J, Samuelson AT, et al. Free Radical Biology and Medicine. 2019;134:268-281.
- Sabbah HN, Gupta RC, Kohli S, et al. Circulation: Heart Failure. 2016;9(2):e002206.
- Chiao YA, Zhang H, Sweetwyne M, et al. eLife. 2020;9:e55513.
- Zhao W, Xu Z, Cao J, Fu Q, et al. Journal of Neuroinflammation. 2019;16(1):230.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108.
- Park JR, Lee H, Kim SI, Yang SR. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417.
- Hsieh MJ, et al. Journal of Molecular Medicine. 2017;95(3):323-333.
- Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin Ξ²4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
- Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of Ageing and Development. 2004;125(2):113-115.
- Brzoska T, Luger TA, Maaser C, Abels C, BΓΆhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives. Endocrine Reviews. 2008;29(5):581-602.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA.gov. Updated 2023.
- World Anti-Doping Agency. The 2025 Prohibited List. WADA. January 1, 2025.
Related Research Questions
Related research
Want the complete research review?
Buy Freedom Research KitβFOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.
